The feasibility of a collaborative double-blind study using an anticoagulant

Cerebrovascular Diseases

Volumn 7, Issue 2, 1997, Pages 100-112

[No Author Info available]

Author keywords

Anticoagulants; Antiphospholipid antibodies; Aspirin; Coagulation; Lupus anticoagulant; Patent Foramen Ovale; Platelet aggregation; Stroke outcome; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE; HEART ATRIUM SEPTUM DEFECT; HEMOSTASIS; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STROKE;

EID: 0003193037     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108175     Document Type: Article

References (59)

1. Sacco RL. Foulkes MA, Mohr JP, Wolf PA, Hier DB, Price TR: Determinants of early recurrence of cerebral infarction: Stroke Data Bank. Stroke 1989:983-989.
2. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpic AGO, and the CATS Group: The Canadian American Ticlopidinc Study (CATS) in Thromboembolic Stroke. Lancet 1989:1215-1220.
3. Sacco RL, Hauser WA, Mohr JP: Hospitalized Stroke in blacks and Hispanies in Northern Manhattan. Stroke 1991:22:1191-1496.
4. Sacco RL, Shi T, Kargman D: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: The Northern Manhattan Stroke Study. Neurology 1994:44:626-634.
5. Chodosh EH, Foulkes MA, Kase CS, Wolf PA, Mohr JP, Hier DB, Price TR, Furtado JO Jr, Silent stroke in the NINCDS Stroke Data Bank. Neurology 1988:38:1674-1679.
6. Bousser MG, Eschwege E, Hagenau M, et al: ‘AICLV controlled trial of Aspirin and dipyridamole in the secondary prevention of alhero-thronibotic cerebral ischaemia. Stroke 1983: 14:5-14.
7. Britton M, Helmers C, Samuelsson K: Higlidose acctylsalicylic acid after cerebral infarction - a Swedish cooperative study. Stroke 1987:18:325-334.
8. Marshall RS, Mohr JP: Current management of ischaemic stroke. J Neurol Ncurosurg Psychiatry 1993:56:6-16.
9. Barnett HJM: Aspirin in stroke prevention: An overview. Stroke 1990:21 (suppl 4):40-43.
10. Antiplatelet Trialists Collaboration: Collaborative overview of randomized trials of anti-platelet treatment. Part I. Prevention of death, myocadial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994:308:81-106.
11. Hass WK, Easton HD, Adams H P. et al. for the Ticlopidinc Aspirin Stroke Study Group: A randomized trial comparing ticlopidinc hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
12. Jonas S: Anticoagulant therapy in cerebrovascular disease: Review and meta-analysis. Stroke 1988:19:1043-104S.
13. Taylor DW, Saekett DL, Haynes RB: Sample size for randomized trials in stroke prevention: How many patients do we need? Stroke 1984: 15:968-971.
14. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators: The effect of low-dosc warfarin on the risk of stroke in patients with nonrhcumatic atrial fibrillation. N Engl J Med 1990:323:1505-1511.
15. The Stroke Prevention in Atrial Fibrillation Investigators: The stroke prevention in atrial fibrillation study: Final results. Circulation 1991:84:527-539.
16. Petersen P, Godtfredsen J, Boysen G.et al: Placebo-controlled. randomized trial of warfare and aspirin for prevention of thromboembolic complications in chronic atria fibrillation: The Copenhagen AFASAK study. Lancet 1989;i: 175-179.
17. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause Steinrauf H, Kurtze JF, Nazarina SM, Radford MJ. et al: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrhcumatic Atrial Fibrillation. N Engl J Med 1992:327:1406-1412.
18. The EAFT Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993:342:1251-1252.
19. The ESPS Group: The European Stroke Prevention Study. Stroke 1990:21:1122-1130.
20. Millcnson MM, Bauer KA, Kistler JP, Barzegar S, Tulin L, Rosenberg RD: Monitoring 'mini-intensitv' anticoagulation with warfarin: Comparison of the prothrombin time using a sensitive thromboplastin with prothrombin fragment r-l+2 levels, Blood 1992:79:2034-2038.
21. Stroke Prevention in Atrial Fibrillation Investigators: Adjusted-dosc warfarin versus low-intensity. fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation. III. Randomised clinical trial. Lancet 1996:348:633-638.
22. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C for the CAFA study investigators: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 1991:18:349-355.
23. North American Symptomatic Carotid Endar-lerectomy Trial Collaborators: Beneficial effect of carotid cndartcrcctomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991:325:445-453.
24. Fleiss JL: Statistical Methods for Rates and Proportions. New York. Wiley. 1981.
25. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Statist Med 1982:1:121-129.
26. Goodman SN, Berlin JA: The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intent Med 1924:121:200-206.
27. Walker AM: Low power and striking results - a surprise but not a paradox (editorial). N Engl J Med 332:1091-1092.
28. Krisher JP, Hurley C, Pillalmarri M, Sangam P, Bleichfeld C, Opel M, Shuster JJ: An automated patient registration and treatment randomization system for multicenler clinical trials. Controlled Clin Trials 1991:12:367-377.
29. Lange N, MacIntyre J: A computerized patient registration and treatment randomization system for multi-institutional clinical trials. Controlled Clinical Trials 1985;6:38-50.
30. Harris EN, Exner T, Hughes GRV, Asherson RA: Phospholipid-binding antibodies. Boca Raton. CRC' Press. 1991.
31. Levine SR, Weleh KMA: The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anti-cardiolipin antibodies. Arch Neurol 1987:44: 876-883.
32. Love PE, Santoro SA: Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SEE) and in non-SLE disorders. Ann Intern Med 1990:112:682-698.
33. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, M, Highes GRV: The 'primary' antiphospholipid syndrome: Major clinical and serological features. Medicine 1989;68:366-374.
34. Maeworth-Young CO, Loizou S, Walporl MJ: Primary antiphospholipid syndrome: Features of patients with raised anticardiolipin antibodies and no other disorder Ann Rheum Dis 1989:48:362-367.
35. Levine SR, Deegan MJ, Futrell N, Welch KMA: Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990:40:1181 -1189.
36. Hess DC, Krauss J, Adams RJ, Nichols FT, Zhang D-I, Rountree H A: Anticardiolipin antibodies: A study of frequency in IIA and stroke. Neurology 1991;41 1525-528.
37. Brcy RL, Hart RG, Sherman DG, Tegeter CH, Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990:40: 1190-1196.
38. Briley DP, C’oull BM, Goodnight SH Jr Neurological disease associated with ant ¡phospholipid antibodies. Ann Neurol 1989:25:221-227.
39. Levine SR, Brey RL, Sawaya KL, Salowieh-Palm L, Kokkinos J, Kostrzema B, Perry M, Haustad S, Carey J: Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995:38:119-124.
40. The Antiphospholipid Antibodies in Stroke Study Group (APASSV). Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993:43:2069-2073.
41. Feldman E, Levine SR: Cerebrovascular disease with antiphospholipid antibodies. Immune mechanisms, significance, and therapeutic options. Ann Neurol 1995:37(51):5114-5130.
42. Hart RG, Miller VT: Cerebral infarctions in young adults: A practical approach. Stroke 1983:14:110-114.
43. Webster MW, Chancellor AM, Smith HJ, Swift DL, Sharpe DN, Bass NM, Glasgow GL: Patent foramen ovule in young stroke patients. Lancet 1988;ii:11-22.
44. Di Tullio M, Sacco RL, Gopal A, Mohr JP, Homnia S: Patent foramen ovale as a risk factor for cryptogenic stroke. Ann Intern Med 1992:117:461-465.
45. Lechal P, Mas JL, Lascault G, Loron P, Theard M, Klimezac M, Drobinski G, Thomas, Gros-gogeat Y: Prevalence of patent foramen ovale in patients with stroke. N Engl J Med 1988: 318:1148-1152.
46. Amarcnco P, Duyckacrts C, Tzourio C, Henin D, Bousser MG, Hauw JJ: The prevalence of ulcerated plaques in the aortic arch in patients with stroke. N Engl J Med 1992:326:221-225.
47. Pearson AC, Nagelhout D, Castello R, Gomez CR, Labovitz AJ: Atrial septal aneurysm and stroke: A transesophageal echocardiographic study. J Am Coll Cardiol 1991:28:1223-1229.
48. Castello R, Pearson AC, Labovitz AJ, Wallace P: Atrial spontaneous contrast in patients undergoing transesophageal echocardiography: Prevalence and clinical implications. Am J Cardiol 1990:65:1149-1153.
49. Goodkin G, Freedberg R, Perez J, Tunick PA, Kronzon I: Valve strands are strongly associated with systemic embolization. J Am Coll Cardiol 1994: February: 129A.
50. Kistler JP, Singer DE, Millenson MM, Bauer KA, Gress R, Barzegar S, Hughes RA, Sheehan MA, Maraventano SW, Ocrtel LB, Rosner B, Rosenberg RD for the BATAAF investigators: Effect of low-intensity warfarin anticoagulation on level of activity of the hemostatic system in patients with atrial fibrillation. Stroke 1993:24: 1360-1365.
51. Cambicn F, Poirier O, Lceerf L, et al: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992:359:641-644.
52. Arbustini E, Grasso M, Fasini R, et al: Angiotensin converting enzyme gene deletion allele is independently and strongly associated with coronary atherosclerosis and myocardial infarction. Br Heart J 1995:74:584-591.
53. Schunkcrt H, Hense H-W, Holmer SR, et al: Association between a deletion polymorphism of the angiotcnsin-converting-enzyme gene and left ventricular hypertrophy. N Engl J Med 1994:330:1634-1638.
54. Raynolds MV, Bristow MR, Bush EW, et al: Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993:342:1073-1075.
55. Marian AJ, Yu Q-t, Workman R, Greve G, Roberts R: Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. Lancet 1993: 342:1085-1086.
56. Markus HS, Barley J, Lunt R, et al: Angioten-sin-coverting enzyme gene deletion polymorphism: A new risk factor for lacunar stroke but not carotid atheroma. Stroke 1995:26:1329-1333.
57. European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10
58. Cannegictcr SC, Rosendaal FR, Winlzen AR, van der Meer FJN, Vandcnbroucke JP, Briet E: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl Med J 1995:333:11-17.
59. Thompson JLP, Fleiss JL, James K, Lazar RM, Marshall R, Chin K, Mohr JP, and the WARSS Study Group: A test of an Algorithm for Simulating Prothrombin Times in a Double-Blind Anticoagulation Drug Trial (abstract). Ann Neurol 1994; 36:305-306.